Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Equity Average: 2020-2025

Historic Equity Average for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to -$10.1 million.

  • Xeris Biopharma Holdings' Equity Average rose 57.64% to -$10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year increase of 57.64%. This contributed to the annual value of -$18.2 million for FY2024, which is 194.77% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Equity Average stood at -$10.1 million for Q3 2025, which was up 62.95% from -$27.2 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Equity Average's 5-year high stood at $95.8 million during Q1 2022, with a 5-year trough of -$32.4 million in Q1 2025.
  • Moreover, its 3-year median value for Equity Average was -$10.1 million (2025), whereas its average is -$7.1 million.
  • In the last 5 years, Xeris Biopharma Holdings' Equity Average spiked by 92.88% in 2021 and then tumbled by 1,886.22% in 2024.
  • Xeris Biopharma Holdings' Equity Average (Quarterly) stood at $46.4 million in 2021, then rose by 8.04% to $50.1 million in 2022, then tumbled by 102.91% to -$1.5 million in 2023, then slumped by 1,886.22% to -$29.0 million in 2024, then soared by 57.64% to -$10.1 million in 2025.
  • Its Equity Average stands at -$10.1 million for Q3 2025, versus -$27.2 million for Q2 2025 and -$32.4 million for Q1 2025.